For the quarter ending 2026-02-28, LEXX has $6,487,303 in assets. $276,997 in debts.
| Balance Sheets | 2026-02-28 | 2025-11-30 | 2025-08-31 | |
|---|---|---|---|---|
| Cash | 5,128,141 | 4,281,233 | 1,802,123 | |
| Short-term investments | 141,266 | 143,267 | 143,267 | |
| Marketable securities | 0 | 0 | 22,093 | |
| Accounts receivable | 42,029 | 88,044 | 368,358 | |
| Prepaid expenses and other current assets | 458,846 | 850,585 | 1,132,504 | |
| Total current assets | 5,770,282 | 5,363,129 | 3,468,345 | |
| Long-term receivables | 64,014 | 64,013 | 64,013 | |
| Right of use assets | 92,018 | 99,485 | 106,816 | |
| Intellectual property, net | 318,058 | 308,060 | 307,818 | |
| Property & equipment, net | 242,931 | 216,120 | 228,129 | |
| Total non-current assets | 717,021 | 687,678 | 706,776 | |
| Total assets | 6,487,303 | 6,050,807 | 4,175,121 | |
| Accounts payable and accrued liabilities | 182,611 | 1,425,433 | 1,463,046 | |
| Deferred revenue | - | - | 0 | |
| Lease liability, current | 32,060 | 31,101 | 30,417 | |
| Total current liabilities | 214,671 | 1,456,534 | 1,493,463 | |
| Lease liabilities - non-current | 62,326 | 70,819 | 78,903 | |
| Total liabilities | 276,997 | 1,527,353 | 1,572,366 | |
| Authorized 220,000,000 common voting shares with a par value of 0.001 per share common shares issued and outstanding 24,887,446 and 19,559,179 at february 28, 2026 and august 31, 2025, respectively | 24,888 | 22,226 | 19,559 | |
| Additional paid-in capital | 73,138,652 | 70,022,365 | 66,501,086 | |
| Accumulated deficit | -66,505,599 | -65,055,620 | -63,460,613 | |
| Accumulated other comprehensive loss | -55,444 | -76,079 | -70,335 | |
| Equity attributable to shareholders of lexaria | 6,602,497 | 4,912,892 | 2,989,697 | |
| Non-controlling interest | -392,191 | -389,438 | -386,942 | |
| Total stockholders' equity | 6,210,306 | 4,523,454 | 2,602,755 | |
| Total liabilities and stockholders' equity | 6,487,303 | 6,050,807 | 4,175,121 | |
Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. (LEXX)